Anika Q4 rev flat, FY rev -6%; guides 2026 rev $114-122.5M; GC Colleran to depart May 1

Anika Therapeutics, Inc.

2025-FY EPS reported -$0.76 revenue$112,819,000

Q4 revenue $30.6M flat YoY; GAAP EPS $0.13, adjusted EPS $0.31; gross margin 63%.
FY25 revenue $112.8M (-6%); GAAP loss ($0.70)/share; adjusted EPS $0.11; adjusted EBITDA $5.3M.
Commercial Channel rev +22% Q4, +15% FY; OEM -12% Q4, -17% FY.
FY26 guidance: rev $114-122.5M (1-9% growth); adj. EBITDA margin 5-10%; $15M buyback continuing.
EVP, General Counsel David Colleran to depart May 1, 2026 under transition agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.